Back

Impact of Tafamidis on clinical outcomes in real-world patients with ATTR-CM

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Amyloid and acute heart failure therapy advances Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ines Araujo

Centro Hospitalar Universitário Lisboa Norte, Lisbon (Portugal)

6 More presentations in this session

Presentation thumbnail
Pillars of heart failure therapy: improving LV function in conventional cardiac pacing
Assistant Professor L. Cirin (Timisoara, RO)
Abstract Slides Video
Presentation thumbnail
SGLT2 inhibitor use in underweight patients with diabetes mellitus and heart failure
Doctor Y. Fujimoto (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Pre- and post- discharge implementation of medical therapy in patients hospitalized due to acute heart failure: a multinational observational registry
Doctor M. Manzoni (Brescia, IT)
Abstract Slides Video
Presentation thumbnail
Risk of all-cause mortality and heart failure hospitalizations in patients treated with vericiguat in real world settings
Doctor F. Kerwagen (Wuerzburg, DE)
Abstract Slides Video
Presentation thumbnail
Mineralocorticoid receptor antagonists in heart failure with mildly reduced and preserved ejection fraction: an updated systematic review and meta-analysis of randomized clinical trials
Doctor D. Rodolico (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Amyloid and acute heart failure therapy advances

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
thumbnail
Congress Presentation
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population
thumbnail
Congress Presentation
12-Month effect of Tafamidis on the clinical progression of cardiac amyloidosis in a single centre cohort

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources